Case Type: Mergers & Acquisitions

Virtusa Corporation (VRTU) related to its sale to Baring Private Equity Asia. Under the terms of the agreement, Virtusa shareholders will receive $51.35 per share for each share of Virtusa stock owned.

Trine Acquisition Corp, Inc. (TRNE) related to the busienss combination with Desktop Metal for its 3D printing business.

Aimmune Therapeutics, Inc. (AIMT) related to its sale to Sociétés des Produits Nestlé, S.A. Under the terms of the agreement, Aimmune shareholders will receive $34.50 per share for each share of Aimmune stock owned.

Immunomedics, Inc. (IMMU) related to its sale to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders will receive $88.00 per share for each share of Immunomedics stock owned.

BMC Stock Holdings, Inc. (BMCH) related to its sale to Builders First Source, Inc. Under the terms of the agreement, BMC shareholders will receive 1.3125 shares of Builder First Source stock for each share of BMC stock owned.

Akcea Therapeutics, Inc. (AKCA) related to its sale to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, Akcea shareholders will receive $18.15 in cash for each share of Akcea common stock owned.

Rosetta Stone Inc. (RST) related to its sale to Cambium Learning Group. Under the terms of the agreement, Rosetta Stone shareholders will receive $30 in cash for each share of Rosetta Stone stock owned.

OncBioMune Pharmaceuticals, Inc. (OBMP) related to its merger with Avant Diagnostics, Inc. Under the terms of the agreement, OBMP will acquire all of the outstanding assets of Avant diagnostic in exchange for a number of shares of its Series D-1 Preferred Convertible Stock, with current shareholders of OBMP expected to own 45.5% of the common … Read more

Broadway Financial Corporation (BFYC) related to its merger with CFBanc Corporation. Under the terms of the agreement, CFBanc shareholders will receive 13.626 shares of Broadway Financial common stock for each share of CFBanc common stock they own, resulting in Broadway Financial stockholders owning 52.5% and CFBanc shareholders owning 47.5% of the combined company.

Proteostasis Therapeutics, Inc. (PTI) related to its merger with Yumanity Therapeutics. Under the terms of the agreement, Proteostasis will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of Proteostasis common stock, with existing Proteostasis shareholders expected to own approximately 32.5% of the combined company.